The treatment of moderate to severe hyponatraemia in patients with decompensated liver disease is unsatisfactory. We report our preliminary experience using intravenous infusion of albumin to treat this condition. Three patients with cirrhosis, ascites, and hyponatraemia responded satisfactorily to treatment; one patient with fulminant hepatitis B did not respond. Intravenous albumin infusion is a safe and effective therapy for patients with cirrhosis complicated by hyponatraemia. Its main role may be in preparing patients for surgery, particularly liver transplantation.
Hyponatraemia is a common complication in cirrhotic patients with ascites and is associated with a poor prognosis particularly if there is associated renal impairment.' As prolonged hyponatraemia of even modest degree (125 mmol/l) may result in irreversible neurological damage2 it has been suggested that hyponatraemia should be treated in patients with liver disease once the serum sodium falls below 130 mmol/1. 3 There is evidence that increasing the intravascular volume corrects many of the fluid and electrolyte problems in patients with cirrhosis. Repleting intravascular volume by head-out water immersion I or by infusing saline"4 or albumin and saline8 is followed by an increase in urinary free water clearance in many cirrhotic patients. The fact that a significant fraction of infused albumin rapidly leaks out into the extravascular space in cirrhotic patients'5 may explain why albumin had to be given repeatedly to maintain the serum sodium level in patient 1. This is best given as 20% albumin as this involves the infusion ofless sodium chloride and therefore less risk of aggravating ascites.
The alternatives to intravenous albumin infusions in hyponatraemic patients include fluid restriction,3 peritoneal dialysis,4 haemofiltration,5 oral urea6 or oral tetracycline.7 Vigorous fluid restriction is unpleasant and may prove impossible if the patient is encephalopathic or otherwise uncooperative. Oral urea is unpleasant to take, causes diarrhoea and is relatively ineffective.'6 Demeclocycline is more effective but may be nephrotoxic.7 Peritoneal dialysis has been reported to be very effective by RingLarsen et al. All patients in their study, however, also received significant amounts, 200 to 300 g of intravenous albumin, to compensate for protein loss in the dialysate. We suggest that the improvement in serum sodium in their study may have been due, at least in part, to the albumin infusion and that perhaps peritoneal dialysis was unnecessary.
Albumin infusion does not correct the basic underlying cause of the hypontraemia and thus the effects are temporary. If the patient is being considered for liver transplantation, however, as in patients 1 and 2, temporary correction of hyponatraemia may be advantageous. Correction of hyponatraemia preoperatively may prevent some of the neurological complications seen after transplantation."' It may also be useful when the hyponatraemia has been aggravated by diuretic therapy as in patient three and symptoms demand that the electrolyte disorder be corrected relatively quickly.
